Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
F&G: 63
6.440,59 S&P · 16,10 Vola-Index · 119.757,31 BTC · 1,16747 EURUSD
Systemstatus: 54.537 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
AGP8696W1045
Letzte Aktualisierung: 12.08.2025 | 7PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG000D0D8P5
SVA
Sinovac Biotech Ltd
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
NAME
Sinovac Biotech Ltd
ISIN
AGP8696W1045
TICKER
SVA
MIC
XNAS
REUTERS
SVA.OQ
BLOOMBERG
SVA US
Do., 10.07.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan an...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 09.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sino...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 09.07.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction s...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Mi., 02.07.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo’s motion for a preliminary injunction ag...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 02.07.2025       Sinovac Bio
AGP8696W1045

Third paragraph, second sentence of release should read: These include the current Board’s failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac’s prior public accounting firm to resign in April, and it...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 02.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company’s outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners’ ten highly qualified director candidates to ...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Di., 01.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board’s empty promises to shareholders, numerous failures overseeing the Company, and c...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Di., 24.06.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to its fellow Sinovac shareholders exposing the current Sinovac Board’s failure to act in the interest of all shareholders resulting ...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
So., 22.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern D...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 18.06.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nomin...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Di., 17.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the Company’s continued false, misleading and outright fabricated c...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mo., 16.06.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac’s Board of Directors (the “Board”) in...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mo., 16.06.2025       Sinovac Bio
AGP8696W1045

The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust ...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Sa., 14.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued the following letter in response to the Company’s recent false and misleading claims relating ...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Fr., 13.06.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 11.06.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today sent a letter to shareholders. *** Dear Fellow Sinovac Shareholders, We, Vivo Capital (“Vivo”), write to you as fellow...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 11.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the ...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Fr., 23.05.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq Listing Rule 5250...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Mi., 30.04.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET....
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Di., 29.04.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitim...
weiterlesen
Sinovac Bio
Research & Analysen Termsheet Terminal
Permalink
Silent Ad

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S